{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:59:46Z","timestamp":1778227186503,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2015.02.012","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T12:14:08Z","timestamp":1439900048000},"page":"S161-S166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"S","title":["Investigating the Role of JAK\/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562"],"prefix":"10.1016","volume":"15","author":[{"given":"Ceyda Tunakan","family":"Dalg\u0131\u00e7","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bur\u00e7in Tezcanl\u0131","family":"Kaymaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melda C\u00f6mert","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015feg\u00fcl","family":"Dalm\u0131zrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahri","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.012_bib1","first-page":"161","article-title":"Imatinib mesylate and the management of chronic myeloid leukemia (CML)","volume":"22","author":"Koca","year":"2005","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.clml.2015.02.012_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.012_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/shem.2003.50044","article-title":"Molecular monitoring of chronic myeloid leukemia","volume":"40","author":"Hughes","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2015.02.012_bib4","first-page":"117","article-title":"Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib in chronic phase and blast crisis chronic myelogenous leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.02.012_bib5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.02.012_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2015.02.012_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/annonc\/mdm223","article-title":"Dasatinib: a new step in molecular target therapy","volume":"18","author":"Olivieri","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.02.012_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00277-010-0948-7","article-title":"Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia case","volume":"89","author":"Han","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.02.012_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl","volume":"21","author":"Eck","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.clml.2015.02.012_bib10","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2002-04-1204","article-title":"Signal transducer and activator of transcription proteins in leukemias","volume":"101","author":"Benekli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.012_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02258360","article-title":"Activation of STAT transcription factors in oncogenic tyrosine kinase signaling","volume":"5","author":"Garcia","year":"1998","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.clml.2015.02.012_bib12","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","article-title":"STATs in oncogenesis","volume":"19","author":"Bowman","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2015.02.012_bib13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.clml.2015.02.012_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0","article-title":"Activation of STAT proteins and growth control","volume":"23","author":"Bromberg","year":"2001","journal-title":"Bioessays"},{"key":"10.1016\/j.clml.2015.02.012_bib15","first-page":"230","article-title":"Chronic myeloid leukemia: \u201carchetype\u201d of the impact of targeted therapies","volume":"60","author":"Nasr","year":"2012","journal-title":"Pathol Biol"},{"key":"10.1016\/j.clml.2015.02.012_bib16","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.onc.1203480","article-title":"Divergent roles of Stat1 and Stat5 in malignancy as revealed by gene disruptions in mice","volume":"19","author":"Levy","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2015.02.012_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1600-0609.2004.00242.x","article-title":"The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells","volume":"72","author":"Ba\u015bkiewicz-Masiuk","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.02.012_bib18","first-page":"58","article-title":"Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis","volume":"3","author":"Kaymaz","year":"2013","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.clml.2015.02.012_bib19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-06-0446","article-title":"Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells","volume":"6","author":"Nam","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2015.02.012_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.leukres.2012.10.011","article-title":"Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8; 21)(q22; q22) and the N822K c-kit mutation","volume":"37","author":"Mpakou","year":"2013","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T01:51:55Z","timestamp":1537408315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":20,"alternative-id":["S2152265015000415"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the Role of JAK\/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}